Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
| Descriptor ID |
D002289
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
| Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 9 | 0 | 9 |
| 2008 | 12 | 0 | 12 |
| 2009 | 7 | 3 | 10 |
| 2010 | 3 | 1 | 4 |
| 2011 | 10 | 3 | 13 |
| 2012 | 13 | 0 | 13 |
| 2013 | 11 | 2 | 13 |
| 2014 | 13 | 2 | 15 |
| 2015 | 12 | 1 | 13 |
| 2016 | 14 | 3 | 17 |
| 2017 | 15 | 1 | 16 |
| 2018 | 9 | 2 | 11 |
| 2019 | 15 | 1 | 16 |
| 2020 | 14 | 3 | 17 |
| 2021 | 8 | 0 | 8 |
| 2022 | 16 | 0 | 16 |
| 2023 | 15 | 0 | 15 |
| 2024 | 9 | 4 | 13 |
| 2025 | 11 | 2 | 13 |
| 2026 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Health care use and costs associated with clinically impactful immune-related adverse events during immune checkpoint inhibitor therapy for non-small cell lung cancer. J Manag Care Spec Pharm. 2026 Aug; 32(8):979-993.
-
Methylation signatures distinguish non-small cell lung cancer subtypes and are associated with survival in smokers with lung squamous cell carcinoma. J Natl Cancer Inst. 2026 Jul 01; 118(7):1299-1312.
-
Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease - A SEER-Medicare study. J Geriatr Oncol. 2026 May; 17(4):102971.
-
Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. Sci Rep. 2026 Apr 04; 16(1).
-
Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026 Aug; 172(2):433-449.e10.
-
Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [18F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integr Cancer Ther. 2026 Jan-Dec; 25:15347354251410182.
-
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. Nat Commun. 2026 Jan 14; 17(1):1726.
-
Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. Int J Radiat Oncol Biol Phys. 2026 Jul 01; 125(3):949-958.
-
Platelet inhibition delays time to neurosurgical intervention for cerebral metastasis in non-small cell lung cancer. Sci Rep. 2025 Nov 04; 15(1):38467.